Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lack of Vitamin D may be linked to dementia

This article was originally published in The Tan Sheet

Executive Summary

Researchers should investigate whether vitamin D deficiency is linked to Alzheimer's disease, says William Grant of the Sunlight, Nutrition and Health Research Center. He explains in the May 2009 issue of the Journal of Alzheimer's Disease that low serum levels of 25-hydroxyvitamin D are associated with cardiovascular disease, diabetes and oral health - all of which are risk factors for or precede dementia

You may also be interested in...

NIST offers Vitamin D SRM

The National Institute of Standards and Technology offers a new standard reference material, SRM 972, for vitamin D in human serum. The material will help labs more accurately measure patients' vitamin D levels so physicians can diagnose accurately when people are deficient, NIST said. It added physicians are testing vitamin D levels more in part because recent studies link low levels of vitamin D to increased risk of certain diseases (1"The Tan Sheet" June 1, 2009)

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts